Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CAPTOPRIL

All products: Limited Use (codes 707, 723)

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Noyada · DIN 02543907 · 5mg/5mL · Oral Sol

Limited Use — Reason for Use code 707, 723 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 707, 723 required
Write on scriptLU code 707, 723 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 707, 723
Reason for Use code 707 For pediatric patients (less than 18 years of age) where the appropriate dose cannot be achieved using a listed solid oral dosage form of captopril. Coverage limit: LU Authorization Period: 1 year Coverage limit: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for this drug product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Reason for Use code 723 For patients unable to swallow or tolerate solid oral dosage forms of captopril. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Noyada · DIN 02543907 Manufacturer: Ethypharm Inc.; listing date 2025-10-31 Health Canada: Marketed since 2024-10-28 · brand NOYADA · ATC C09AA01 CAPTOPRIL · form Solution · route Oral · ingredients CAPTOPRIL 5 MG/5ML · company Ethypharm inc · schedule Prescription
Check this DIN again · Health Canada product record

Noyada: Formulary list price $0.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103233 · Verify on the e-Formulary ↗ (DIN 02543907)

Source record
DIN 02543907: Noyada Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240800312; group id 316; item number 0699; lccId 00419; manufacturer id ETH Source form: Oral Sol; strength: 5mg/5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6000; ministry $0.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02543907 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103233
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543907
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: or renovascular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ENALAPRIL MALEATE · Listed, not a benefit (1), General benefit (51)  essential or renovascular hypertension PM: https://pdf.hres.ca/dpd_pm/00061923.PDF; date not captured; DIN 00670901; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Hypertension APO-CAPTO (captopril) is indicated for the treatment of essential or renovascular hypertension. It is usually administered in association with other drugs, particularly thiazide diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. In using APO-CAPTO, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). a) In patients with normal renal function. APO-CAPTO should normally be used in those patients in whom treatment with diuretics or beta-blockers was found ineffective or has been associated with unacceptable adverse effects. APO-CAPTO can be tried as an initial agent in those patients with severe hypertension or in those in whom the use of diuretics and/or beta-blockers is contraindicated or in patients with medical conditions in which those drugs frequently cause serious adverse effects. b) In patients with impaired renal function. In these patients, particularly those with collagen vascular disease, captopril should be reserved for hypertensives wh… https://pdf.hres.ca/dpd_pm/00022606.PDF PM date: November 1, 2013 Source product: APO-CAPTO TAB 12.5MG; DIN 00893595; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.